Latest Developments in Stem Cell Research and Regenerative Medicine, September 2016

    January 2017 in “ Regenerative Medicine ”
    Duško Ilić, Cristina Trento
    TLDR In September 2016, there were major advancements and promising clinical trials in stem cell research and regenerative medicine.
    In September 2016, significant advancements in stem cell research and regenerative medicine were made, including key collaborations and promising clinical trials. Notable partnerships involved Cynata Therapeutics and FUJIFILM for iPSC-derived MSC products, and L'Oréal with Poietis for bioprinting hair follicles. Clinical trials showed promising results, such as Asterias Biotherapeutics' AST-OPC1 for spinal cord injury and Bluebird Bio's LentiGlobin for β-thalassemia. Juno Therapeutics' JCAR014 for non-Hodgkin lymphoma had a 50% complete response rate, and Kerastem's Phase II trial on pattern baldness using fat-based stem cells was completed. Other significant developments included FDA and EMA designations for various therapies and substantial grants awarded to advance stem cell-based treatments.
    Discuss this study in the Community →